If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Anna Guidetti is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 19 Similar Profiles
Hodgkin Disease Medicine & Life Sciences
Granulocyte Colony-Stimulating Factor Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Stem Cells Medicine & Life Sciences
Multiple Myeloma Medicine & Life Sciences
SCID Mice Medicine & Life Sciences
Monophenol Monooxygenase Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2001 2019

Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival

Spina, F., Radice, T., De Philippis, C., Soldarini, M., Di Chio, M. C., Dodero, A., Guidetti, A., Viviani, S. & Corradini, P., Jan 2 2019, In : Leukemia and Lymphoma. 60, 1, p. 101-109 9 p.

Research output: Contribution to journalArticle

Homologous Transplantation
Stem Cell Transplantation
Graft vs Host Disease
Hodgkin Disease

Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes? HemaSphere

Chiappella, A., Crombie, J., Guidetti, A., Vitolo, U., Armand, P. & Corradini, P., 2019, In : Hemasphere. 3, 5, p. e284

Research output: Contribution to journalArticle

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma

Dodero, A., Guidetti, A., Tucci, A., Barretta, F., Novo, M., Devizzi, L., Re, A., Passi, A., Pellegrinelli, A., Pruneri, G., Miceli, R., Testi, A., Pennisi, M., Di Chio, M. C., Matteucci, P., Carniti, C., Facchetti, F., Rossi, G. & Corradini, P., Apr 1 2019, In : Leukemia. 33, 4, p. 1047-1051 5 p.

Research output: Contribution to journalLetter

Open Access

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

Trnĕný, M., Verhoef, G., Dyer, M. J., Ben Yehuda, D., Patti, C., Canales, M., Lopez, A., Awan, F. T., Montgomery, P. G., Janikova, A., Barbui, A. M., Sulek, K., Terol, M. J., Radford, J., Guidetti, A., Di Nicola, M., Siraudin, L., Hatteville, L., Schwab, S., Oprea, C. & 1 others, Gianni, A. M., Aug 2018, In : Haematologica. 103, 8, p. 1351-1358 8 p.

Research output: Contribution to journalArticle

Lymphoma, Large B-Cell, Diffuse
Multicenter Studies
Anti-Idiotypic Antibodies
Pharmaceutical Preparations

Efficacy of antibody-drug conjugate brentuximab vedotin in treating Hodgkin's lymphoma

Viviani, S. & Guidetti, A., Aug 2018, In : Expert Opinion on Biological Therapy. 18, 8, p. 841-849 9 p.

Research output: Contribution to journalArticle

Hodgkin Disease
Pharmaceutical Preparations
Refractory materials